Abemaciclib is indicated for the treatment of women with hormone receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||06/07/2020|
|Rapid review completed||27/08/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib (Verzenios®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|